Connect with us

Research

Higher triglycerides levels linked to lower risk of dementia

Published

on

Older people who have higher levels of triglycerides, a type of fat, may have a lower risk of dementia and a slower cognitive decline over time compared to people who have lower levels, according to new research.

While a link was found, it does not prove that higher levels of triglycerides prevent dementia, the study, published in Neurology, the medical journal of the American Academy of Neurology, said.

Triglycerides are fatty acids and are the most common type of fat in the blood. Triglycerides contribute up to 95% of dietary fats, which are the main energy source of the brain.

“Higher triglyceride levels may be reflective of better overall health and lifestyle behaviors that would protect against dementia,” said study author Zhen Zhou of Monash University in Melbourne, Australia.

“Our findings suggest that triglyceride levels may serve as a useful predictor for dementia risk and cognitive decline in older populations.”

Researchers used health care data to identify 18,294 people in one cohort with an average age of 75 who did not have a prior diagnosis of Alzheimer’s disease or dementia.

Participants were followed for an average of six years. During that time, 823 people developed dementia.

Researchers looked at participants’ measurements of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL) each year of the study.

Then researchers divided participants into four groups based on fasting triglyceride levels. Of the total group, average triglycerides were 106 milligrams per decilitre (mg/dL).

For adults, a normal or healthy triglyceride level is below 150 mg/dL.

Lower risk

After adjusting for variables including education and cholesterol-lowering treatments, researchers found every doubling of triglyceride levels was associated with an 18% lower risk of developing dementia.

The lowest triglyceride group had levels of less than 62 mg/dL. The second group had levels of 63 to 106 mg/dL. Compared to the lowest group, the second group was 15% less likely to develop dementia.

The third group had levels of 107 to 186 mg/dL. Compared to the lowest group, they were 24% less likely to develop dementia.

The fourth group had levels of 187 mg/dL or higher. Compared to the lowest group, they were 36% less likely to develop dementia.

Of the 1,416 people in the lowest triglyceride group, 82 people, or 6%, developed dementia. Of the 7,449 people in the second group, 358 people, or 5%, developed dementia.

Of the 7,312 people in the third group, 310, or 4%, developed dementia. Of the 2,117 people in the fourth group, 73 people, or 3%, developed dementia.

The researchers also validated their results in another dataset comprised of 68,200 older people from the UK.

Among them, 2,778 people developed dementia over an average time of 12 years. They observed a consistent result which shows a 17% decreased risk of dementia with every doubling of triglycerides levels.

Researchers also found that higher triglycerides were also associated with slower decline in composite cognition, a combined result from tests of global function, psychomotor speed, language and executive function and memory over time.

“Future studies are needed to investigate whether specific components within triglycerides may promote better cognitive function, with the hope of developing new preventive strategies,” Zhou said.

A limitation of the study was researchers looked only at people 65 and older who had no cognitive issues initially, so the findings are not generalisable to other populations.

The study was supported by the National Institute on Aging, Royal Australian College of General Practitioners and HCF Research Foundation.

Research

How older people explore new spaces could suggest dementia

Published

on

Results from a new study have shown an analogous shift in exploration behaviour in middle age for the first time in humans.

Spatial navigation – the ability to select and follow a route from one place to another – is a skill we use every day. Depending on practice, general cognitive ability, and childhood environment, some people are naturally better at this than others.

However, research has also shown that people’s skill in spatial navigation tends to decrease with increasing age.

This decline in navigation skill has been generally attributed to worsening spatial memory, due to changes in brain structure and function that naturally occur with age. But what if it isn’t just due to our spatial memory declining, but also to changes in how we explore a novel environment? Such a shift has been observed in aging animals, ranging from insects to rodents and fish.

An exploratory study

Results from this new study, published in Frontiers in Aging Neuroscience, could have clinical applications.

First author Dr Vaisakh Puthusseryppady, a postdoctoral researcher at the University of California at Irvine, stated: “Compared to younger individuals, middle-aged people exhibit overall less exploration when learning a novel maze environment, and seem to be prioritising learning specific important locations in the maze as opposed to the overall maze layout.”

Puthusseryppady and colleagues recruited 87 middle-aged (on average 50 years old) and 50 young (on average 19 years old) women and men as volunteers. None had a history of neurologic disease including dementia, or psychiatric illness.

The researchers tested how well the volunteers explored and learned to navigate a maze in virtual reality. The maze was composed of crossroads and corridors, separated by hedges. Distinctive objects were scattered around it at strategic locations as landmarks. In the first ‘exploration phase’, the volunteers were instructed to freely explore the maze and learn the locations of the objects.

In each of the 24 trials in the second ‘wayfinding phase’, the volunteers had to apply what they had learnt, navigating between two randomly chosen objects within 45 seconds.

As expected, young people on average had a greater success rate in finding their way. But importantly, further statistical analyses showed that this difference in success rate was partially driven by observed qualitative changes in how young vs middle-aged participants learned about the maze.

“Compared to younger individuals, middle-aged individuals explored the maze environment less, as they travelled less distance, paused for longer periods of time at decision points, and visited more objects than young individuals,” said Dr Mary Hegarty, a professor at the Department of Psychological and Brain Sciences of the University of California at Santa Barbara, and a joint corresponding author.

These differences were so notable, the authors were able to predict using artificial intelligence whether a participant was middle-aged or young.

Pointing the way for applications

Reduced exploration in middle-aged people may be due to age-related changes in the brain’s navigation network, for example the medial temporal and parietal lobes.

The authors speculated that these findings could inform training interventions that can help middle-aged adults to improve their navigation abilities and preserve cognitive ability.

Co-author Daniela Cossio, a PhD student at the University of California at Irvine, explained: “If we were to train middle-aged people to explore novel environments better – with a focus on traveling greater distances, visiting paths that connect the environment, in a more spread-out manner – this might lead to improvements in their spatial memory, helping to slow down their decline in cognitive ability.”

Dr Elizabeth Chrastil, one of the corresponding authors, and an associate professor at the same institute, looked ahead: “We are currently investigating whether these kinds of changes in exploration behaviour can be identified in people at risk of Alzheimer’s Disease, as well as in those who actually have Alzheimer’s.

“We anticipate that altered exploration behaviour could ultimately become a novel clinical marker for early cognitive decline related to Alzheimer’s.”

Continue Reading

Research

Lung cancer screening prolongs lives in real-world study

Published

on

Among US veterans diagnosed with lung cancer through the Veterans Health Administration healthcare system, those who underwent screening before diagnosis were more likely to be diagnosed with earlier stage disease and had a higher cure rate than those who had not been screened.

Lung cancer is the leading cause of cancer deaths worldwide, and most patients are diagnosed at an advanced stage.

Early detection through screening could save lives, and current recommendations state that adults 50–80 years old with at least a 20-pack-year smoking history who currently smoke or have quit within the past 15 years should undergo annual imaging tests for lung cancer.

Such screening has been shown to be beneficial in clinical trials, but there are limited data on the real-world effectiveness of lung cancer screening. To investigate, researchers assessed the impact of screening among patients in the Veterans Health Administration healthcare system diagnosed with lung cancer from 2011–2018.

Among 57,919 individuals diagnosed with lung cancer, 2,167 (3.9%) underwent screening before diagnosis. Patients who underwent screening had higher rates of early (stage I) diagnoses compared with those who had no screening (52% versus 27%), lower rates of death from any cause (49.8% versus 72.1%), and death from cancer (41.0% versus 70.3%) over 5 years.

“It is incredible to witness how dedicated national efforts to increase lung cancer screening from the Lung Precision Oncology Program can lead to substantial improvements in lung cancer outcomes,” said co–corresponding author Michael Green, MD, PhD, of the University of Michigan and the Veterans Affairs Ann Arbor Healthcare System.

The findings come from an observational study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Continue Reading

Research

Pioneering therapy approach to combat age-related vision loss

Published

on

Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a revolutionary treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Featured on the cover of the journal Science Translational Medicine, this breakthrough research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD.

AMD can severely impact a person’s vision. Patients suffering from AMD often start with blurred vision or seeing a black dot in their central vision, which can ultimately expand to the point where there is no useful central vision. Currently, AMD affects approximately 200 million people worldwide, a number projected to rise to 288 million by 2040 with graying populations.

The exact cause of AMD is complex and thought to involve a combination of aging, environmental, and lifestyle factors.

The team found that augmenting IRAK-M levels in retinal cells can significantly protect against retinal degeneration.

“This discovery represents the first pathway-agnostic approach toward AMD, offering a comprehensive treatment option for the millions of people who suffer from this debilitating condition,” said Dr. Andrew Dick, Head of the Academic Unit of Ophthalmology at the University of Bristol, Director of the UCL Institute of Ophthalmology, and co-founder and Chief Scientific Advisor of Cirrus Therapeutics.

Dr. Jian Liu, the first author and senior research scientist at the Academic Unit of Ophthalmology of the University of Bristol, added: “Since age stands as a primary risk factor for AMD, the gradual decrease of IRAK- M levels with age, which further declines in AMD, is a key way to identify the potential markers of early AMD progression and ultimately a new way of treatment.”

This discovery will build and improve upon current treatments for AMD, which are targeting single pathophysiology pathways. “Our novel approach not only addresses the multiple pathways involved in treating AMD but also offers the most compelling and evidence-based strategy available today,” said Cirrus Therapeutics co-founder and Chief Executive Officer Dr. Ying Kai Chan.

Cirrus Therapeutics recently spun out of the University of Bristol to develop therapies related to this discovery.

The research for this paper was funded by the Rosetrees Trust, Stoneygate Trust, Underwood Trust, Macular Society, Sight Research UK, Moran Eye Center at the University of Utah, Sharon Eccles Steele Center for Translation, and supported by the National Institute for Health and Care Research (NIHR) BRC Moorfields and UCL-Institute of Ophthalmology.

Continue Reading

Trending